PRELUDE THERAPEUTICS INC (PRLD) Stock Earnings & Estimates
NASDAQ:PRLD - US74065P1012 - Common Stock
1.31 USD
+0.03 (+2.34%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7M | -100.00% | 19.319M | 56.241M 191.12% | 100.52M 78.73% | 158.06M 57.24% | 233.15M 47.51% | |||||
| EBITDA YoY % growth | -122.22M -8.33% | -131.108M -7.27% | -137.942M -5.21% | -170.968M -23.94% | -185.985M -8.78% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -123.54M -8.62% | -132.277M -7.07% | -139.714M -5.62% | -142.412M -1.93% | -145.451M -2.13% | -155.546M -6.94% | -179.893M -15.65% | -110.124M 38.78% | -37.221M 66.20% | 8.696M 123.36% | 67.747M 679.06% | |
| Operating Margin | N/A | N/A | -1,995.91% | N/A | N/A | N/A | -931.17% | -195.81% | -37.03% | 5.50% | 29.06% | |
| EPS YoY % growth | -2.44 -0.83% | -2.03 16.80% | -1.69 16.75% | -1.45 14.10% | -1.04 28.39% | -0.83 19.71% | -1.28 -52.75% | -0.75 40.80% | -0.41 45.95% | 0.04 110.00% | 0.45 1,000.00% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.39 8.62% | -0.28 26.72% | -0.34 20.22% | -0.34 18.15% | -0.34 13.04% | -0.34 -23.08% | -0.28 15.68% | -0.25 24.32% | -0.27 20.90% | -0.30 11.90% | -0.30 -7.22% | -0.30 -20.08% |
| Revenue Q2Q % growth | -100.00% | -100.00% | N/A | N/A | N/A | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -34.057M 0.93% | -33.528M 0.90% | -36.009M 7.35% | -36.19M 0.29% | -36.37M -6.79% | -36.553M -9.02% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.41 10.87% | -0.45 | 0.04 | 8.54% |
| Q1 2025 Q2Q % growth | -0.42 | -0.48 | 0.06 | 12.08% |
| Q4 2024 Q2Q % growth | -0.38 17.39% | -0.47 | 0.09 | 19.59% |
| Q3 2024 Q2Q % growth | -0.43 4.44% | -0.48 | 0.05 | 10.65% |
| Q2 2024 Q2Q % growth | -0.46 14.81% | -0.44 | -0.02 | -4.88% |
| Q1 2024 Q2Q % growth | -0.42 27.59% | -0.49 | 0.07 | 15.10% |
| Q4 2023 Q2Q % growth | -0.46 23.33% | -0.50 | 0.04 | 7.96% |
| Q3 2023 Q2Q % growth | -0.45 28.57% | -0.59 | 0.14 | 24.24% |
| Q2 2023 Q2Q % growth | -0.54 6.90% | -0.65 | 0.11 | 16.41% |
| Q1 2023 Q2Q % growth | -0.58 7.94% | -0.70 | 0.12 | 16.99% |
| Q4 2022 Q2Q % growth | -0.60 15.49% | -0.64 | 0.04 | 6.33% |
| Q3 2022 Q2Q % growth | -0.63 4.55% | -0.65 | 0.02 | 2.89% |
| Q2 2022 Q2Q % growth | -0.58 | -0.62 | 0.04 | 6.78% |
| Q1 2022 Q2Q % growth | -0.63 -34.04% | -0.66 | 0.03 | 4.98% |
| Q4 2021 Q2Q % growth | -0.71 -57.78% | -0.70 | -0.01 | -1.99% |
| Q3 2021 Q2Q % growth | -0.66 87.43% | -0.64 | -0.02 | -3.53% |
| Q2 2021 Q2Q % growth | -0.58 | -0.50 | -0.08 | -15.11% |
| Q1 2021 Q2Q % growth | -0.47 | -0.43 | -0.04 | -8.68% |
| Q4 2020 Q2Q % growth | -0.45 | -0.48 | 0.03 | 5.63% |
| Q3 2020 Q2Q % growth | -5.25 | -0.44 | -4.81 | -1,096.99% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0% | 8.53% | 14.31% |
| Revenue | N/A | N/A | N/A | N/A |